Literature DB >> 23873337

Risk of functional impairment in Facioscapulohumeral muscular dystrophy.

Jeffrey M Statland1, Rabi Tawil.   

Abstract

INTRODUCTION: Facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent muscular dystrophies. Nevertheless, little is known about the risk of developing functional impairment. Here we determine the 6-year risk of functional impairment in FSHD.
METHODS: A retrospective cohort of 313 genetically confirmed, clinically affected FSHD participants in a United States registry between January 2002 and June 2011. Our main outcome was wheelchair (WC) use.
RESULTS: The 6-year risk of WC use was 24.0% (95% confidence interval 18.6-29.3). The distribution of WC risk was bimodal, with a peak in the second decade associated with large D4Z4 contractions, followed by an age-related increase in risk. Other functional categories showed moderate risk. Prevalence of hearing aid use and difficulty pronouncing words was increased in large D4Z4 contractions.
CONCLUSIONS: The 6-year risk of functional impairment in FSHD is moderate, and early WC use is associated with large D4Z4 contractions.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  D4Z4 contraction; Facioscapulohumeral dystrophy; Functional impairment; Muscular dystrophy; Neuromuscular disorders

Mesh:

Year:  2014        PMID: 23873337     DOI: 10.1002/mus.23949

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  27 in total

Review 1.  Facioscapulohumeral Muscular Dystrophy.

Authors:  Jeffrey M Statland; Rabi Tawil
Journal:  Continuum (Minneap Minn)       Date:  2016-12

2.  Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.

Authors:  Bryan P Fitzgerald; Kelly M Conn; Joanne Smith; Andrew Walker; Amy L Parkhill; James E Hilbert; Elizabeth A Luebbe; Richard T Moxley
Journal:  J Neurol       Date:  2016-10-12       Impact factor: 4.849

Review 3.  Facioscapulohumeral Dystrophy.

Authors:  Leo H Wang; Rabi Tawil
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

4.  An instrumented timed up and go in facioscapulohumeral muscular dystrophy.

Authors:  Jessie Huisinga; Adam Bruetsch; Ayla Mccalley; Melissa Currence; Laura Herbelin; Omar Jawdat; Mamatha Pasnoor; Mazen Dimachkie; Richard Barohn; Jeffrey Statland
Journal:  Muscle Nerve       Date:  2017-10-06       Impact factor: 3.217

5.  AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD.

Authors:  Carlee R Giesige; Lindsay M Wallace; Kristin N Heller; Jocelyn O Eidahl; Nizar Y Saad; Allison M Fowler; Nettie K Pyne; Mustafa Al-Kharsan; Afrooz Rashnonejad; Gholamhossein Amini Chermahini; Jacqueline S Domire; Diana Mukweyi; Sara E Garwick-Coppens; Susan M Guckes; K John McLaughlin; Kathrin Meyer; Louise R Rodino-Klapac; Scott Q Harper
Journal:  JCI Insight       Date:  2018-11-15

6.  Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies.

Authors:  Jeffrey M Statland; Bharati Shah; Don Henderson; Silvere Van Der Maarel; Stephen J Tapscott; Rabi Tawil
Journal:  Muscle Nerve       Date:  2015-06-18       Impact factor: 3.217

7.  A multinational study on motor function in early-onset FSHD.

Authors:  Jean K Mah; Jia Feng; Marni B Jacobs; Tina Duong; Kate Carroll; Katy de Valle; Cara L Carty; Lauren P Morgenroth; Michela Guglieri; Monique M Ryan; Paula R Clemens; Mathula Thangarajh; Richard Webster; Edward Smith; Anne M Connolly; Craig M McDonald; Peter Karachunski; Mar Tulinius; Amy Harper; Avital Cnaan; Yi-Wen Chen
Journal:  Neurology       Date:  2018-03-14       Impact factor: 9.910

8.  Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Authors:  Rabi Tawil; John T Kissel; Chad Heatwole; Shree Pandya; Gary Gronseth; Michael Benatar
Journal:  Neurology       Date:  2015-07-28       Impact factor: 9.910

Review 9.  Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy.

Authors:  Bo Bao; Rika Maruyama; Toshifumi Yokota
Journal:  Intractable Rare Dis Res       Date:  2016-08

Review 10.  Facioscapulohumeral muscular dystrophy.

Authors:  Jeffrey Statland; Rabi Tawil
Journal:  Neurol Clin       Date:  2014-05-15       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.